Skip to main content

Advertisement

SpringerLink
Log in

The anticonvulsants market

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

An Erratum to this article was published on 01 May 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Shifting market composition for anticonvulsant drugs.
Figure 2: Sales revenue (2008) of key anticonvulsant brands split by indication.

References

  1. World Health Organization. Epilepsy: key facts. WHO website [online], (2009).

  2. Cereghino, J. J. et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55, 236–242 (2000).

    Article  CAS  Google Scholar 

  3. Beran, R. G. et al. Efficacy and safety of levetiracetam 1000–3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res. 63, 1–9 (2005).

    Article  CAS  Google Scholar 

  4. Morrell, M. J. et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 56, 209–120 (2003).

    Article  CAS  Google Scholar 

  5. Sridharan, R. Epidemiology of epilepsy. Curr. Sci. 82, 664–670 (2002).

    Google Scholar 

  6. Datamonitor. Pipeline and commercial insight: neuropathic pain — evaluation of the current and future market dynamics, DMHC2403 (October 2008).

  7. Pfizer. Press release 21 Jun 2007: Pfizer's Lyrica receives FDA approval for fibromyalgia based on expedited review. Pfizer website [online], (2007).

  8. Datamonitor. Commercial and pipeline insight: fibromyalgia — approvals legitimize condition and expose underserved patient population, DMHC2405 (July 2008).

  9. Takeshima, T. et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache 44, 8–19 (2004).

    Article  Google Scholar 

  10. Sanchez-Perez, R. et al. A descriptive study of migraine in a rural population of Area del Comtat. Rev. Neurol. 28, 373–376 (1999).

    CAS  PubMed  Google Scholar 

  11. Silberstein, S. D., Neto, W., Schmitt, J. & Jacobs, D. for the MIGR-001 Study Group. Topiramate in migraine prevention: results of a large, controlled trial. Arch. Neurology 61, 490–495 (2004).

    Article  Google Scholar 

  12. MIDAS sales data and Prescribing Insight. (IMS Health, 2009).

  13. Datamonitor. Commercial insight: anticonvulsants — non-epilepsy indication expansions provide blockbuster potential, DMHC2544 (October 2009).

Download references

Author information

Authors and Affiliations

  1. Charlotte Mackey is a pharmaceuticals and healthcare analyst with Datamonitor, 119 Farringdon Road, London EC1R 3ER, UK. cmackey@datamonitor.com ,

    Charlotte Mackey

Authors
  1. Charlotte Mackey
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mackey, C. The anticonvulsants market. Nat Rev Drug Discov 9, 265–266 (2010). https://doi.org/10.1038/nrd3076

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3076

  • Springer Nature Limited

This article is cited by

Search

Navigation